Categories
Uncategorized

Cerveau Technologies, Inc. Signs Research Agreement with Kobe City Hospital Organisation, Japan

At Cerveau Technologies we’re working towards the vision of globally developing diagnostics and technology in partnership with Enigma Biomedical Group and Sinotau Pharmaceutical Group. In turn, these developments can have a profoundly positive impact on patients suffering from neurodegenerative disorders, like Alzheimer’s disease.

On June 22, Cerveau Technologies has signed an exciting agreement, one with the Kobe City Hospital Organization in Japan. This partnership will support multiple projects over the next coming years focused on manufacturing and supplying the [18F]MK-6240 needed for initiatives located in the Kansai area.

The research projects will explore studies entered around the early stage imaging agent (MK-6420) and how this can be utilized in Positron Emission Tomography (PET) scans in order to assess and analyz1218-brain-scan-algorithm-future-technology-timelinee the status and progression of the neurofibrillary tangles (NFTs) in the brain.

These NFTs are the most commonly known markers of  neurodegenerative diseases like Alzheimer’s, made up of abnormal accumulations of a protein called tau.

Dr. Michio Senda, MD, PhD, Director of Molecular Imaging at Kobe City Medical Center General Hospital (KCGH), which is managed by Kobe City Hospital Organization (KCHO), stated “Tau-PET imaging is an excellent tool of visualizing and evaluating neurofibrillary tangles in the living human brain affected by Alzheimer’s disease, tauopathies, or other brain disorders. It is also valuable for clinical trials of therapeutic drugs for those diseases, which will be facilitated in Japan by the collaboration with Cerveau.”

Together, Cerveau and Kobe city will benefit patients with brain diseases. the collaboration with KCHO will further and support the global production network in Europe, Canada, Japan, China, Singapore, Australia and the United States.

Categories
Uncategorized

Enigma Biomedical Group and Invicro Sign a Collaboration Agreement

iStock-695372158_ehealth

 

At Enigma Biomedical group, we’re focused on molecular imaging and medicine. We’re on a mission to progress developmental studies in brain health and accelerate them by offering an array of services, so that they’re able to impact the world on a vast, global scale.

From vaccine development to the revolution of genomics, we’re here to set a new standard of excellence.

Just last month, Enigma Biomedical Group announced an exciting collaboration with Invicro.

You may have heard of this company before; they’re the leading provider of imaging services  and software in translational drug discovery and development. It’s all very exciting, and a step forward in brain health analysis.

Consistent with our vision, they’ll be focusing on the enhancement of Invicro’s Amyloid and Tau platforms. Together, Enigma Biomedical Group and Invicro will be working on multiple projects focused on neurodegeneration paired with a streamlined approach,

“We are extremely impressed by the Enigma portfolio and look forward to a great research partnership in the coming years” stated Dr. Jack Hoppin, Co-Founder and CEO of Invicro.

the-possibilities-and-the-future-of-brain-hackingThis partnership means many things, notable ones being broadening our access to the scientific public through biomarkers imaging and breakthrough algorithms and accelerating the neuro imaging clinical trials. This will support all of the informatics available to the medical community (like the pharmaceutical industry and our academic partners).

“This is an important step in accelerating critical biomarker research projects globally and supporting our pharmaceutical partners efforts to combat neurodegenerative disease.” States Lee-Anne Gibbs, President of Enigma Biomedical Group, “collaborating with Invicro’s IQ technology platform allows Enigma and our partners Cerveau and Meilleur, to continue to execute the collective strategy of providing biomarkers to industry and academics to accelerate research in the field of Neurodegenerative disease.”

Enigma is looking forward to this partnership and many more that will align with their mission and broaden access to novel research.